Form 8-K

8-K — Sensus Healthcare, Inc.

Accession: 0001753926-26-000782

Filed: 2026-05-07

Period: 2026-05-07

CIK: 0001494891

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — g085707_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (g085707_ex99-1.htm)

GRAPHIC (img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: g085707_8k.htm · Sequence: 1

false

0001494891

2026-05-07

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

DC 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): May 7, 2026

SENSUS

HEALTHCARE, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-37714

27-1647271

(State of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

851 Broken Sound Pkwy., NW # 215, Boca Raton, Florida

33487

(Address of principal executive offices)

(Zip Code)

Registrant's

telephone number, including area code: (561) 922-5808

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant

under any of the following provisions (see General Instruction A.2. below):

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title of

each class Trading

Symbol(s) Name

of each exchange on which registered

Common

Stock, par value $0.01 per share SRTS Nasdaq Stock Market, LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

SENSUS

HEALTHCARE, INC.

FORM

8-K

CURRENT

REPORT

Item

2.02 Results

of Operation and Financial Condition

May 7, 2026, Sensus Healthcare, Inc. announced via press release its financial results for the first quarter of 2026. A copy of

the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The

press release makes reference to certain non-GAAP financial measures. A reconciliation of the non-GAAP financial measures and

other financial information is provided in the press release.

The

information furnished under Item 2.02, including in Exhibit 99.1, shall not be deemed “filed” for purposes of Section

18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities

Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d)

Exhibits

99.1 Press

Release, dated May 7, 2026.

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf

by the undersigned hereunto duly authorized.

SENSUS

HEALTHCARE, INC.

Date: May

7, 2026

By:

/s/

Javier Rampolla

Chief Financial Officer

EXHIBIT

INDEX

Exhibit

Number

Description

99.1

Press Release, dated May 7, 2026.

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: g085707_ex99-1.htm · Sequence: 2

Exhibit

99.1

Sensus

Healthcare Reports First Quarter 2026 Financial Results and Business Highlights

Dedicated

CPT Codes for Superficial Radiotherapy (SRT) Now Effective, Driving Increased Customer Activity, Customer Diversification and

Improved Physician Economics

Sales

Pipeline and Financing Activity Strengthen Following Reimbursement Clarity

Expansion

of Installed Base and Recurring Revenue Growth Driving Advancement Towards Profitability

Exited

the Quarter with $18.3 Million in Cash and No Debt

BOCA

RATON, Fla., May 7, 2026 – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing

highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results

and business highlights for the three months ended March 31, 2026.

Highlights

included:

● Revenue

of $3.4 million compared to $8.3 million for the three months ended March 31, 2025.

o Excluding

sales to the Company’s historically largest customer, revenue increased from $2.7

million in the quarter ended March 31, 2025.

● Shipped

14 SRT systems (10 direct sales and 4 placements under Fair Deal Agreement program and

rental arrangements) compared to 30 systems shipped in the prior-year period (21 direct

sales and 9 Fair Deal Agreement program placements).

o None

of the quarter’s direct sales were to the Company’s historically largest

customer, compared to 15 in the prior-year period.

● Dedicated

CPT Codes for SRT and IG-SRT, effective January 1, 2026, provide reimbursement certainty

for the treatment of non-melanoma skin cancer.

o Company

experienced increased inquiry levels, stronger pipeline activity, and greater customer

engagement from dermatology practices and hospitals following implementation of new CPT

Codes.

● Continued

expansion of the Fair Deal Agreement program, with treatment volumes increasing 8% over

the first quarter of 2025.

o 18

active sites and 9 sites pending activation as of March 31, 2026.

● Launched

Sensus Healthcare Financial Services to further support customer acquisition and financing

flexibility.

● Introduced

Sensus Link, providing advanced operating capabilities to the SRT-100™ installed

base.

● Ended

the quarter with $18.3 million in cash and cash equivalents and no debt.

Management

Commentary

“During

the first quarter, we began our efforts in educating and training our existing customer base as well as our many new prospects.

We are seeing the benefits of the dedicated CPT Codes for superficial radiotherapy move from concept to commercial reality,”

said Joseph Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. “With these codes now in effect, physicians

have greater reimbursement visibility and substantially improved economics to offer SRT and IG-SRT for the treatment of non-melanoma

skin cancer, including an approximately 300% increase in the per-fraction delivery code. We believe this will meaningfully improve

the quality of our sales pipeline, increase customer engagement, shorten the decision-making process for many prospective customers

and, importantly, support continued diversification of our customer base.

“We

also continued to grow our customer base through expansion of our Fair Deal Agreement program, the launch of Sensus Healthcare

Financial Services, and increased interest among independent practices, group networks, and hospitals that historically had not

adopted SRT. In addition, the introduction of Sensus Link represents an important step in our strategy to expand higher-margin

recurring revenue streams by bringing enhanced workflow, treatment documentation and operating intelligence capabilities to our

installed base.

“As

we enter this new reimbursement environment, we are focused on five priorities for 2026: education and training, accelerating

customer adoption, expanding recurring revenue, broadening our commercial reach, and driving Sensus toward profitability,”

concluded Sardano.

First

Quarter 2026 Financial Results

Revenues

were $3.4 million compared to $8.3 million for the three months ended March 31, 2025. The decrease in revenue was primarily due

to the absence of sales to the Company’s historically largest customer and a lower number of units shipped. In addition,

some systems placed during the quarter were under Fair Deal Agreement program and rental arrangements, for which revenue is recognized

over the term of the agreement rather than at the time of shipment.

Excluding

sales to the Company’s historically largest customer for the three months ended March 31, 2025, revenue increased compared

to $2.7 million, reflecting continued progress in diversifying the customer base.

Cost

of sales was $2.4 million compared to $4.0 million for the prior-year period. The decrease was primarily driven by a lower number

of units sold, reflecting the absence of sales to the Company’s historically largest customer in the current quarter, as

well as a shift toward placements under Fair Deal Agreement program and rental arrangements.

Gross

profit was $1.0 million compared to $4.4 million for the prior-year period. Gross margin was 29.2% in the first quarter of 2026,

compared to 52.2% in the corresponding period in 2025. The decrease in gross profit and margin was primarily driven by product

mix, including a higher proportion of international shipments, which carry lower average selling prices, and costs associated

with new system placements under the Company’s Fair Deal Agreement program, under which revenue is recognized over the term

of the agreement.

General

and administrative expense was $2.0 million compared to $2.2 million for the three months ended March 31, 2025. The net decrease

in general and administrative expense was primarily due to lower professional fees.

Selling

and marketing expense was $1.7 million compared to $2.2 million for the three months ended March 31, 2025, a decrease of $0.5

million. The decrease was primarily driven by a reduction in tradeshow expenses.

Research

and development expense was $1.6 million compared to $2.6 million for the three months ended March 31, 2025, a decrease of $1.0

million. The decrease was primarily due to reductions in lobbying costs related to billing code reimbursement, headcount, and

product development for next generation systems.

Adjusted

EBITDA for the first quarter of 2026 was negative $4.2 million, compared with negative $2.5 million for the first quarter of 2025.

Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation

expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the reasons these non-GAAP financial

measures are provided.

Other

income of $0.1 and $0.2 million for the three months ended March 31, 2026, and 2025, respectively relates primarily to interest

income.

Net

loss was $2.6 million, or $0.16 per share, compared with net loss of $2.6 million, or $0.16 per share, for the three months ended

March 31, 2025.

Cash

and cash equivalents were $18.3 million as of March 31, 2026, compared with $22.1 million as of December 31, 2025. The Company

had no outstanding borrowings under its revolving line of credit at March 31, 2026. Prepaid inventory was $2.5 million compared

with $1.6 million as of December 31, 2025. Inventories were $16.5 million compared with $14.6 million as of December 31, 2025.

Conference

Call and Webcast

Sensus

Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management

will discuss these financial results, provide a business update and answer questions.

Participants

are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass

the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register

can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask

the operator to be connected to the Sensus Healthcare conference call.

The

call will be webcast live and can be accessed at this link or in the Investor Relations section of the Company’s

website at www.sensushealthcare.com.

Use

of Non-GAAP Financial Information

This

press release contains supplemental financial information determined by methods other than in accordance with accounting principles

generally accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure,

in its analysis of the Company’s performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures,

nor should it be viewed as a substitute for operating results determined in accordance with GAAP. Non-GAAP financial measures

are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare.

As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice

of some investment analysts who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort

comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.

(unaudited)

For the Three Months Ended

March 31,

(in thousands)

2026

2025

Net loss, as reported

$ (2,626 )

$ (2,572 )

Add:

Depreciation

Stock compensation expense

Income tax (benefit) expense

(1,607 )

110

Interest income, net

(125 )

(184 )

Adjusted EBITDA, non-GAAP

$ (4,192 )

$ (2,481 )

About

Sensus Healthcare

Sensus

Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging

its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly

effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare

offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

Forward-Looking

Statements

This

press release includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these statements

can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,”

“expects,” “plans,” “intends,” “may,” “could,” “might,”

“will,” “should,” “approximately,” “potential” or negative or other variations

of those terms or comparable terminology, although not all forward-looking statements contain these words.

Forward-looking

statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus Healthcare,

Inc., our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer

or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances

are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments

in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press

release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial

condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking

statements contained in this press release as a result of the following factors, among others: the level and availability of government

and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers

to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including

the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies

that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our

ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other

foreign countries, including ongoing geopolitical tensions between the U.S. and China; legislation, regulation, or other governmental

action that affects our products, taxes, international trade regulation (including the possibility of tariffs and fluctuations

in tariffs on equipment we export or materials we import), or other aspects of our business; the performance of the Company’s

information technology systems and its ability to maintain data security; the possibility that inflationary pressures continue

to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and

our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described

from time to time in our filings with the Securities and Exchange Commission.

date, the geopolitical uncertainties other than those relating to China have not had any significant impact on our business, but

we continue to monitor developments and will address them in future filings, if applicable.

Any

forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no

obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be

required by applicable law. You should read carefully the introductory note regarding forward-looking statements and the factors

described in the “Risk Factors” section included in our periodic reports filed with the Securities and Exchange Commission

to better understand the risks and uncertainties inherent in our business.

Investor

Relations Contact

Leigh

Salvo

New

Street Investor Relations

leigh@newstreetir.com

SENSUS

HEALTHCARE, INC.

CONSOLIDATED

STATEMENTS OF OPERATIONS

For the Three Months Ended

March 31,

(in thousands, except share and per share data)

2026

2025

(unaudited)

Revenues

$ 3,394

$ 8,344

Cost of sales

2,403

3,990

Gross profit

991

4,354

Operating expenses:

General and administrative

2,043

2,208

Selling and marketing

1,716

2,186

Research and development

1,590

2,606

Total operating expenses

5,349

7,000

Loss from operations

(4,358 )

(2,646 )

Other income:

Interest income, net

125

184

Other income, net

125

184

Loss before income tax

(4,233 )

(2,462 )

(Benefit from) provision for income taxes

(1,607 )

110

Net loss

$ (2,626 )

$ (2,572 )

Net loss per share - basic

$ (0.16 )

diluted

$ (0.16 )

Weighted average number of shares used in computing

net loss per share - basic

16,462,653

16,341,867

diluted

16,462,653

16,341,867

SENSUS

HEALTHCARE, INC.

CONSOLIDATED

BALANCE SHEETS

(in

thousands, except share and per share data)

As of March 31,

2026

of December 31,

2025

(unaudited)

Assets

Current assets

Cash and cash equivalents

$ 18,327

$ 22,083

Accounts receivable, net

3,578

6,041

Inventories

16,500

14,563

Prepaid inventory

2,478

1,522

Other current assets

1,707

1,683

Total current assets

42,590

45,892

Property and equipment, net

2,314

1,976

Deferred tax asset

5,686

4,079

Operating lease right-of-use assets, net

390

452

Other noncurrent assets

566

640

Total assets

$ 51,546

$ 53,039

Liabilities and stockholders’ equity

Current liabilities

Accounts payable and accrued expenses

$ 4,692

$ 3,343

Product warranties

262

275

Operating lease liabilities, current portion

267

262

Deferred revenue, current portion

639

842

Total current Liabilities

5,860

4,722

Operating lease liabilities, net of current portion

140

209

Deferred revenue, net of current portion

Total liabilities

6,004

4,941

Commitments and contingencies

Stockholders’ equity

Preferred stock, 5,000,000 shares authorized and none issued and outstanding

—

Common stock, $0.01 par value - 50,000,000 authorized; 17,055,095 issued

and 16,462,059 outstanding at March 31, 2026; 17,056,845 issued and 16,463,809 outstanding at December 31, 2025

169

Additional paid-in capital

46,160

46,090

Treasury stock, 593,036 shares at cost, at March 31, 2026 and December 31, 2025

(3,876 )

Retained earnings

3,089

5,715

Total stockholders’ equity

45,542

48,098

Total liabilities and stockholders’

equity

$ 51,546

$ 53,039

GRAPHIC

Filename: img001.jpg · Sequence: 6

Binary file (4682 bytes)

Download img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 07, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 07, 2026

Entity File Number

001-37714

Entity Registrant Name

SENSUS

HEALTHCARE, INC.

Entity Central Index Key

0001494891

Entity Tax Identification Number

27-1647271

Entity Incorporation, State or Country Code

Entity Address, Address Line One

851 Broken Sound Pkwy.

Entity Address, Address Line Two

NW # 215

Entity Address, City or Town

Boca Raton

Entity Address, State or Province

Entity Address, Postal Zip Code

33487

City Area Code

(561)

Local Phone Number

922-5808

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.01 per share

Trading Symbol

SRTS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration